These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 29914893)

  • 1. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
    Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
    J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer.
    Tavukcuoglu E; Horzum U; Yanik H; Uner A; Yoyen-Ermis D; Nural SK; Aydin B; Sokmensuer C; Karakoc D; Yilmaz KB; Hamaloglu E; Esendagli G
    Eur J Immunol; 2020 Dec; 50(12):2067-2074. PubMed ID: 32691408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients.
    Bruderek K; Schirrmann R; Brandau S
    Methods Mol Biol; 2021; 2236():1-7. PubMed ID: 33237535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD66b
    Horzum U; Yoyen-Ermis D; Taskiran EZ; Yilmaz KB; Hamaloglu E; Karakoc D; Esendagli G
    Cancer Immunol Immunother; 2021 Jan; 70(1):75-87. PubMed ID: 32632664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
    Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
    J Leukoc Biol; 2024 May; 115(6):1094-1107. PubMed ID: 38369808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
    Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
    Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
    Rodriguez PC; Ernstoff MS; Hernandez C; Atkins M; Zabaleta J; Sierra R; Ochoa AC
    Cancer Res; 2009 Feb; 69(4):1553-60. PubMed ID: 19201693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
    Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
    Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
    Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
    Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
    Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
    Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.